

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-45 (Canceled)

46. (Currently Amended) A pharmaceutical composition ~~comprising~~consisting essentially of a phosvitin or fragment thereof which is at least 10% dephosphorylated and a pharmaceutically-acceptable carrier, wherein the pharmaceutical composition is not an aqueous solution or a lyophilized material.

47-48 (Canceled)

49. (Previously presented) The composition of Claim 46 wherein the phosvitin is chicken phosvitin.

50. (Previously presented) The composition of Claim 280 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

51. (Original) The composition of Claim 50 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

52 (Original) The composition of Claim 51 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

53. (Original) The composition of Claim 52 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

54-80 (Canceled)

81. (Currently Amended) A kit for contacting a cell, a tissue or an organ that has been removed from an animal, the kit comprising:

(a) a container holding a phosvitin or fragment thereof which is at ~~least 10%~~least 70% dephosphorylated; and

(b) instructions describing how to use the kit to contact a cell, tissue or organ with the phosvitin or fragment thereof in the kit.

82-185 (Canceled)

186. (Currently Amended) A pharmaceutical composition which is formulated for topical administration to an animal and which is not an aqueous solution, the composition

Appl. No. 10/723,247
Amdt. dated May 19, 2010
Reply to Office Action mailed May 19, 2010

~~comprising~~ consisting essentially of a phosvitin or fragment thereof which is at least 10% dephosphorylated and a pharmaceutically-acceptable carrier.

187-193 (Canceled)

194. (Previously presented) The composition of Claim 186 wherein the phosvitin is chicken phosvitin.

195. (Previously presented) The composition of Claim 186 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

196. (Previously presented) The composition of Claim 195 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

197. (Previously presented) The composition of Claim 196 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

198. (Previously presented) The composition of Claim 197 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

199. (Previously presented) The composition of Claim 198 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

200-216 (Canceled)

217. (Previously presented) The pharmaceutical composition of any one of Claims 186, 195-199 or 288 which is formulated for topical administration to the skin of an animal.

218. (Previously presented) The pharmaceutical composition of any one of Claims 186, 195-199 or 288 which is drops, a spray, an aerosol or an inhalant.

219. (Previously presented) The pharmaceutical composition of any one of Claims 186, 195-199 or 288 which is a powder or a foam.

220. (Previously presented) The pharmaceutical composition of any one of Claims 186, 195-199 or 288 which is a lotion, a gel, a cream, an ointment or a paste.

221-245 (Canceled)

246. (Previously presented) The pharmaceutical composition of Claim 220 which is an ointment or a cream.

247-271 (Canceled)

272. (Previously presented) A pharmaceutical composition comprising a phosvitin or fragment thereof which is at least 10% dephosphorylated and has a targeting molecule covalently attached to it and a pharmaceutically-acceptable carrier.

273. (Previously presented) The composition of Claim 272 wherein the composition is formulated for topical administration to an animal.

274-279 (Canceled)

280. (Previously presented) The composition of Claim 46 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

281. (Previously presented) The composition of Claim 53 wherein the phosvitin or fragment thereof is unphosphorylated.

282. (Previously presented) The composition of Claim 49 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

283. (Previously presented) The composition of Claim 282 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

284. (Previously presented) The composition of Claim 283 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

285. (Previously presented) The composition of Claim 284 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

286. (Previously presented) The composition of Claim 285 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

287. (Previously presented) The composition of Claim 286 wherein the phosvitin or fragment thereof is unphosphorylated.

288. (Previously presented) The composition of Claim 199 wherein the phosvitin or fragment thereof is unphosphorylated.

289. (Previously presented) The composition of Claim 194 wherein the phosvitin or fragment thereof is at least about 20% dephosphorylated.

290. (Previously presented) The composition of Claim 289 wherein the phosvitin or fragment thereof is at least about 35% dephosphorylated.

291. (Previously presented) The composition of Claim 290 wherein the phosvitin or fragment thereof is at least about 50% dephosphorylated.

292. (Previously presented) The composition of Claim 291 wherein the phosvitin or fragment thereof is at least about 70% dephosphorylated.

293. (Previously presented) The composition of Claim 292 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

294. (Previously presented) The composition of Claim 293 wherein the phosvitin or fragment thereof is unphosphorylated.

295. (Previously presented) The pharmaceutical composition of any one of Claims 194 or 289-294 which is formulated for topical administration to the skin of an animal.

296. (Previously presented) The pharmaceutical composition of any one of Claims 194 or 289-294 which is drops, a spray, an aerosol or an inhalant.

297. (Previously presented) The pharmaceutical composition of any one of Claims 194 or 289-294 which is a powder or a foam.

298. (Previously presented) The pharmaceutical composition of any one of Claims 194 or 289-294 which is a lotion, a gel, a cream, an ointment or a paste.

299. (Previously presented) The pharmaceutical composition of Claim 298 which is an ointment or a cream.